Showing results (411-420 of 436) with videos related to

Sort By:
Pageof 44
Translational Lung Cancer Research|January 13, 2023
Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohortZihua Zou, Yangchun Gu, Li Liang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2026
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 StudyLisa Licitra, Makoto Tahara, Kevin Harrington, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 25, 2025
Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition)Yan-Song Lin, Ren-Fei Wang, Rui Huang, et al.
Blood|October 6, 2023
Clonal evolution dissection reveals that a high MSI2 level promotes chemoresistance in T-cell acute lymphoblastic leukemiaJingliao Zhang, Yongjuan Duan, Peng Wu, et al.
JAMA|March 13, 2025
Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical TrialRobert Haddad, Jérôme Fayette, Maria Teixeira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2025
GFH018 and toripalimab combination therapy for previously treated recurrent or metastatic nasopharyngeal carcinoma: Results from a phase 1b/2 studyLin-Quan Tang, Sai-Lan Liu, Muh-Hwa Yang, et al.
Future Oncology (London, England)|March 4, 2026
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or <i>HER2</i>-mutant solid tumorsAlison M Schram, John J Park, Antoine Italiano, et al.
Cancer Letters|February 1, 2025
Phase Ib study of SCT200 combined with paclitaxel or docetaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma following platinum-based chemotherapy and PD-1 antibodyJinguan Lin, Song Qu, Kunyu Yang, et al.
Cancer Treatment Reviews|November 18, 2025
Expert consensus on the combination of Anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinomaLiqiong Xue, Tingting Xu, Guochun Cao, et al.
The Oncologist|June 29, 2026
Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective studyBohan Li, Chengjuan Luo, Jun Lu, et al.
Pageof 44